

TRANSCATHETER CLOSURE OF SEPTAL DEFECTS

Effective Date: June 1, 2025

Review Dates: 4/07, 4/08, 4/09, 4/10, 4/11, 4/12, 4/13,
5/14, 5/15, 5/16, 5/17, 5/18, 5/19, 5/20, 5/21, 5/22,
5/23, 5/24, 5/25

Date Of Origin: April 11, 2007

Status: Current

Summary of Changes

Changes:

- I. C.: Ventricular septal defects is no longer an exclusion. Ventricular septal defects has been added as indication 4 under I. A.

I. POLICY/CRITERIA

A. Transcatheter closure of septal defects using FDA approved devices may be considered medically necessary for any of the following:

1. Secundum atrial septal defects (ASDs)
2. Patent ductus arteriosus (PDA)
3. Fenestration following a Fontan procedure
4. Ventricular septal defects

B. Transcatheter closure of patent foramen ovale (PFO) may be considered medically necessary for associated cryptogenic stroke, transient ischemic attack, or arterial embolism due to presumed paradoxical embolism through the PFO, when conventional drug therapy (one or more antithrombotics) has failed. The device must be FDA approved (e.g., Amplatzer PFO Occluder) and used as labelled.

C. Transcatheter closure of septal defects is considered not medically necessary for all other indications including, but not limited to:

1. When any of the following conditions are present:
 - Multiple defects that cannot be adequately covered by the device
 - Associated congenital cardiac anomalies that require cardiac surgery
 - Ostium primum atrial septal defects
 - Sinus venosus atrial septal defects
 - Partial anomalous pulmonary venous drainage
 - Pulmonary hypertension
 - Congestive heart failure
 - Sepsis
 - Coagulation disorders in patients who are unable to take antiplatelet or anticoagulant therapy
2. Migraine prophylaxis

3. Transmyocardial (perventricular) transcatheter closure of VSDs
4. Obstructive Sleep Apnea

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the [Priority Health Provider Manual](#).

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:**
- ❖ *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

IV. DESCRIPTION

Background

Transcatheter septal occlusion devices are implantable devices that are used to repair septal wall defects. Atrial or ventricular defects in the septal wall of the heart can have a number of adverse consequences, including abnormal ventricular volume load, ventricular pressure load, mixing of unoxygenated and oxygenated blood and inadequate systemic cardiac output. These abnormalities can lead to cardiac enlargement, pulmonary hypertension, rhythm disturbance, and stroke. Conventional open-heart surgical repair of septal defects carries some risk, especially in patients in whom heart or pulmonary function may be compromised. In addition, there is considerable morbidity associated with open-heart surgery. Moreover, some types of ventricular septal defects (VSDs) are difficult to repair surgically due to their location or orientation. Consequently, there has been considerable interest in the development of a transcatheter method of repairing septal lesions. Access to the defect is achieved through the venous system via the internal jugular vein or femoral vein in the groin.

V. CODING INFORMATION

ICD-10 Codes that may apply:

- G45.0 – G45.9 Transient cerebral ischemic attacks and related syndromes
- I23.1 Atrial septal defect as current complication following acute myocardial infarction
- I51.0 Cardiac septal defect, acquired
- I63.9 Cerebral infarction, unspecified
- Q21.10-Q21.19 Atrial septal defect
- Q21.20-Q21.23 Atrioventricular septal defect
- Q25.0 Patent ductus arteriosus

CPT Codes:

- 93580 Percutaneous transcatheter closure of congenital interatrial communication (i.e., Fontan fenestration, atrial septal defect) with implant
- 93582 Percutaneous transcatheter closure of patent ductus arteriosus

HCPCS Codes:

- C1817 Septal defect implant system, intracardiac
- C2628 Catheter, occlusion

Not Covered

- 93581 Percutaneous transcatheter closure of a congenital ventricular septal defect with implant
- 93799 Unlisted cardiovascular service or procedure (*for transcatheter ventricular septal defect procedure – explanatory notes must accompany claim*)

VI. REFERENCES

1. Carminati M, Butera G, Chessa M, Drago M, Negura D, Piazza L. Transcatheter closure of congenital ventricular septal defect with Amplatzer septal occluders. *Am J Cardiol.* 2005 Dec 19;96(12A):52L-58L. doi: 10.1016/j.amjcard.2005.09.068. Epub 2005 Nov 2. PMID: 16399093.
2. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med.* 2013 Mar 21;368(12):1092-100. doi: 10.1056/NEJMoa1301440. PMID: 23514286.
3. Connolly HM and Ammash NS. Management and prognosis of congenital ventricular septal defect in adults. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on April 8, 2025.)
4. Hayes, Inc. Health Technology Assessment. Transcatheter Closure of Ventricular Septal Defects. Hayes, Inc. July 30, 2008. Annual Review July 13, 2010.
5. Hayes, Inc. Health Technology Assessment. Comparative Effectiveness Review of Transcatheter Closure of Patent Foramen Ovale for Prevention of Recurrent Cryptogenic Stroke. Hayes, Inc. May 31, 2018. Annual Review June 7, 2022.
6. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *N Engl J Med.* 2012 Mar 15;366(11):991-9. doi: 10.1056/NEJMoa1009639. PMID: 22417252.
7. Kapadia SR. Patent foramen ovale closure: historical perspective. *Cardiol Clin.* 2005 Feb;23(1):73-83. doi: 10.1016/j.ccl.2004.10.012. PMID: 15676270.
8. Johnston SC. Patent foramen ovale closure--closing the door except for trials. *N Engl J Med.* 2012 Mar 15;366(11):1048-50. doi: 10.1056/NEJMe1201173. PMID: 22417260.
9. Latson LA, Jones TK, Jacobson J, Zahn E, Rhodes JF. Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder. *Am Heart J.* 2006 May;151(5):1129.e7-11. doi: 10.1016/j.ahj.2006.01.005. PMID: 16644351.
10. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Jüni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med.* 2013 Mar 21;368(12):1083-91. doi: 10.1056/NEJMoa1211716. PMID: 23514285.
11. Messé SR, Kent DM. Still no closure on the question of PFO closure. *N Engl J Med.* 2013 Mar 21;368(12):1152-3. doi: 10.1056/NEJMe1301680. PMID: 23514293; PMCID: PMC4420155.
12. Rome JJ, Kreutzer J. Pediatric interventional catheterization: reasonable expectations and outcomes. *Pediatr Clin North Am.* 2004 Dec;51(6):1589-610, viii. doi: 10.1016/j.pcl.2004.08.007. PMID: 15561175.

13. Wang JK, Tsai SK, Wu MH, Lin MT, Lue HC. Short- and intermediate-term results of transcatheter closure of atrial septal defect with the Amplatzer Septal Occluder. *Am Heart J.* 2004 Sep;148(3):511-7. doi: 10.1016/j.ahj.2004.01.030. PMID: 15389241.

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.